These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 27068473)

  • 1. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
    Marjon K; Cameron MJ; Quang P; Clasquin MF; Mandley E; Kunii K; McVay M; Choe S; Kernytsky A; Gross S; Konteatis Z; Murtie J; Blake ML; Travins J; Dorsch M; Biller SA; Marks KM
    Cell Rep; 2016 Apr; 15(3):574-587. PubMed ID: 27068473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
    Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
    Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
    Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
    J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine.
    Barekatain Y; Ackroyd JJ; Yan VC; Khadka S; Wang L; Chen KC; Poral AH; Tran T; Georgiou DK; Arthur K; Lin YH; Satani N; Ballato ES; Behr EI; deCarvalho AC; Verhaak RGW; de Groot J; Huse JT; Asara JM; Kalluri R; Muller FL
    Nat Commun; 2021 Jul; 12(1):4228. PubMed ID: 34244484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
    Kryukov GV; Wilson FH; Ruth JR; Paulk J; Tsherniak A; Marlow SE; Vazquez F; Weir BA; Fitzgerald ME; Tanaka M; Bielski CM; Scott JM; Dennis C; Cowley GS; Boehm JS; Root DE; Golub TR; Clish CB; Bradner JE; Hahn WC; Garraway LA
    Science; 2016 Mar; 351(6278):1214-8. PubMed ID: 26912360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
    Kalev P; Hyer ML; Gross S; Konteatis Z; Chen CC; Fletcher M; Lein M; Aguado-Fraile E; Frank V; Barnett A; Mandley E; Goldford J; Chen Y; Sellers K; Hayes S; Lizotte K; Quang P; Tuncay Y; Clasquin M; Peters R; Weier J; Simone E; Murtie J; Liu W; Nagaraja R; Dang L; Sui Z; Biller SA; Travins J; Marks KM; Marjon K
    Cancer Cell; 2021 Feb; 39(2):209-224.e11. PubMed ID: 33450196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition.
    Fogal V; Michopoulos F; Jarnuczak AF; Hamza GM; Harlfinger S; Davey P; Hulme H; Atkinson SJ; Gabrowski P; Cheung T; Grondine M; Hoover C; Rose J; Bray C; Foster AJ; Askin S; Majumder MM; Fitzpatrick P; Miele E; Macdonald R; Keun HC; Coen M
    Arch Toxicol; 2024 Aug; 98(8):2589-2603. PubMed ID: 38755480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential and challenges of targeting
    Bray C; Balcells C; McNeish IA; Keun HC
    Front Oncol; 2023; 13():1264785. PubMed ID: 37795443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.
    Barbarino M; Cesari D; Bottaro M; Luzzi L; Namagerdi A; Bertolino FM; Bellan C; Proietti F; Somma P; Micheli M; de Santi MM; Guazzo R; Mutti L; Pirtoli L; Paladini P; Indovina P; Giordano A
    J Cell Mol Med; 2020 May; 24(10):5565-5577. PubMed ID: 32301278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of
    Smith CR; Aranda R; Bobinski TP; Briere DM; Burns AC; Christensen JG; Clarine J; Engstrom LD; Gunn RJ; Ivetac A; Jean-Baptiste R; Ketcham JM; Kobayashi M; Kuehler J; Kulyk S; Lawson JD; Moya K; Olson P; Rahbaek L; Thomas NC; Wang X; Waters LM; Marx MA
    J Med Chem; 2022 Feb; 65(3):1749-1766. PubMed ID: 35041419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition state analogue of MTAP extends lifespan of APC
    Firestone RS; Feng M; Basu I; Peregrina K; Augenlicht LH; Schramm VL
    Sci Rep; 2021 Apr; 11(1):8844. PubMed ID: 33893330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective PRMT5 Inhibitors Suppress Human CD8
    Strobl CD; Schaffer S; Haug T; Völkl S; Peter K; Singer K; Böttcher M; Mougiakakos D; Mackensen A; Aigner M
    Mol Cancer Ther; 2020 Feb; 19(2):409-419. PubMed ID: 31712395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the
    Yu Z; Kuang Y; Xue L; Ma X; Li T; Yuan L; Li M; Xue G; Li Z; Tang F; Tang J; Shan J; Wang W; Tang R; Zhou F
    MedComm (2020); 2024 Oct; 5(10):e705. PubMed ID: 39309689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
    Frau M; Feo F; Pascale RM
    J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous
    Konteatis Z; Travins J; Gross S; Marjon K; Barnett A; Mandley E; Nicolay B; Nagaraja R; Chen Y; Sun Y; Liu Z; Yu J; Ye Z; Jiang F; Wei W; Fang C; Gao Y; Kalev P; Hyer ML; DeLaBarre B; Jin L; Padyana AK; Dang L; Murtie J; Biller SA; Sui Z; Marks KM
    J Med Chem; 2021 Apr; 64(8):4430-4449. PubMed ID: 33829783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A patent review of MAT2a inhibitors (2018-2021).
    Atkinson SJ; Evans L; Scott JS
    Expert Opin Ther Pat; 2022 Oct; 32(10):1043-1053. PubMed ID: 36043503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular 5'-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-binding proteins.
    Tang B; Lee HO; Gupta S; Wang L; Kurimchak AM; Duncan JS; Kruger WD
    J Biol Chem; 2022 Sep; 298(9):102367. PubMed ID: 35963436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.
    Busacca S; Zhang Q; Sharkey A; Dawson AG; Moore DA; Waller DA; Nakas A; Jones C; Cain K; Luo JL; Salcedo A; Salaroglio IC; Riganti C; Le Quesne J; John T; Boutros PC; Zhang SD; Fennell DA
    Sci Rep; 2021 Apr; 11(1):7434. PubMed ID: 33795785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors.
    Chen S; Hou J; Jaffery R; Guerrero A; Fu R; Shi L; Zheng N; Bohat R; Egan NA; Yu C; Sharif S; Lu Y; He W; Wang S; Gjuka D; Stone EM; Shah PA; Rodon Ahnert J; Chen T; Liu X; Bedford MT; Xu H; Peng W
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39313308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis for substrate recruitment to the PRMT5 methylosome.
    Mulvaney KM; Blomquist C; Acharya N; Li R; Ranaghan MJ; O'Keefe M; Rodriguez DJ; Young MJ; Kesar D; Pal D; Stokes M; Nelson AJ; Jain SS; Yang A; Mullin-Bernstein Z; Columbus J; Bozal FK; Skepner A; Raymond D; LaRussa S; McKinney DC; Freyzon Y; Baidi Y; Porter D; Aguirre AJ; Ianari A; McMillan B; Sellers WR
    Mol Cell; 2021 Sep; 81(17):3481-3495.e7. PubMed ID: 34358446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.